Tonix Pharmaceuticals Holding Corp. (TNXP): Price and Financial Metrics


Tonix Pharmaceuticals Holding Corp. (TNXP)

Today's Latest Price: $1.02 USD

0.01 (-0.97%)

Updated Jan 25 6:55pm

Add TNXP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

TNXP Stock Price Chart Interactive Chart >

Price chart for TNXP

TNXP Price/Volume Stats

Current price $1.02 52-week high $2.46
Prev. close $1.03 52-week low $0.39
Day low $0.97 Volume 38,747,000
Day high $1.12 Avg. volume 50,666,594
50-day MA $0.70 Dividend yield N/A
200-day MA $0.77 Market Cap 270.07M

Tonix Pharmaceuticals Holding Corp. (TNXP) Company Bio


Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS"). The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD").


TNXP Latest News Stream


Event/Time News Detail
Loading, please wait...

TNXP Latest Social Stream


Loading social stream, please wait...

View Full TNXP Social Stream

Latest TNXP News From Around the Web

Below are the latest news stories about Tonix Pharmaceuticals Holding Corp that investors may wish to consider to help them evaluate TNXP as an investment opportunity.

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021 CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the World Intellectual Property Organization has published a patent application filed under the Patent Cooperation Treaty covering TNX-1500, a humanized monoclonal antibody (mAb) directed against CD40-ligand, which is also known as CD154, T-BAM, 5c8 antigen, TRAP and gp39. The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. WO 2021/001458 A1. If claims are granted, a patent issuing from a national stage of this application could potentially provid...

Yahoo | January 14, 2021

Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules

CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of $40.0 million before deducting fees and other estimated offering expenses. The Company sold 50,000,000 shares of common stock at $0.80 per share. A.G.P./Alliance Global Partners acted as sole placement agent for the offering.This offering was made pursuant to effective shelf registration statements on Form S-3 (File No. 333-224586 and 333-237610) previously filed and declared effective by the U.S. Securities and Exchange Commission (the “SEC”). This press release shall not constitute an of...

Yahoo | January 13, 2021

Sidoti Virtual Investor Conference

Presentation Times and Weblinks Released for Over 60 Presenting CompaniesNEW YORK, NY / ACCESSWIRE / January 13, 2021 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for its two-day Winter 2021 Virtual Investor Conference, to take place Wednesday and Thursday, January 13-14, 2021. The links can also be found at www.

Yahoo | January 13, 2021

Tonix Pharmaceuticals prices $40M equity offering (NASDAQ:TNXP)

Tonix Pharmaceuticals (TNXP +3.6%) to issue 50M common shares, par value $0.001 per share at $0.80/share in a registered direct offering, priced at-the-mar

Seeking Alpha | January 11, 2021

Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules

CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 50,000,000 shares of common stock, par value $0.001 per share at an offering price of $0.80 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be $40,000,000 before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 13, 2021, subject to the satisfaction of customary closing conditions.  A.G.P./Alliance Global Partners...

Yahoo | January 11, 2021

Read More 'TNXP' Stories Here

TNXP Price Returns

1-mo N/A
3-mo 74.33%
6-mo -23.88%
1-year -37.80%
3-year -99.75%
5-year -99.98%
YTD 51.11%
2020 -42.31%
2019 -94.68%
2018 -93.62%
2017 -26.60%
2016 -93.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.89 seconds.